Rajesh Jari, MD
Interventional Pain Medicine · Nottingham, MDNPI 1427194356
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (45.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by International Rehabilitative Sciences, Inc at 46.0% of the total. Reporting peaked in 2024 at $8,937 and has fallen 87.3% since, to $1,133 in 2025.
Across 482 payments — averaging $54.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$12K
- Abbott$4K
- Nevro Corp.$2K
- Medtronic$1K
- Spinal Simplicity, LLC$1K
- Vertos Medical, Inc.$612
- plus $5K from 36 others
What the payments were for
- Consulting fees$1,7086%
- Travel & lodging$1,0194%
- Food & beverage$11,58744%
- Other$12,15446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RS4I PLUS SEQUENTIAL STIMULATOR$12,154
- RS-LBG, RS-FBG$7,164
- Proclaim Family of SCS IPGs$2,181
- HA MINUTEMAN G3-R$1,049
- INTELLIS ADAPTIVESTIM$393
- Omnia$385
- Eon Family of SCS IPGs$274
- INTELLIS$271
- mild Device Kit$240
- VANTA ADAPTIVESTIM$163
- XLIF$136
How this compares
$26,468 in reported general payments places this provider in the 80th percentile of 56 interventional pain medicine providers in Maryland.
See all interventional pain medicine providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 626 | $9,639 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 141 | $4,973 |
| Celecoxib | 169 | $4,738 |
| Gabapentin | 186 | $2,243 |
| Pregabalin | 90 | $2,145 |
| Cyclobenzaprine Hcl | 65 | $1,640 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 95 | $1,556 |
| Lidocaine | 12 | $1,530 |
| Morphine Sulfate ErMorphine Sulfate | 37 | $1,109 |
| Fentanyl | 13 | $1,017 |
| Tramadol Hcl | 153 | $903 |
| Tizanidine Hcl | 75 | $668 |
| Diclofenac Sodium | 23 | $639 |
| Duloxetine Hcl | 11 | $357 |
| Hydromorphone Hcl | 21 | $332 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Nottingham
- Felix GurmanNottingham$12K
- Mark ColemanPikesville$1.3M
- Marc LoevRockville$318K
- Anish PatelFrederick$311K
- Aneesh SinglaSalisbury$167K
- Charles SimmonsAnnapolis$62K
- Ali El-MohandesHagerstown$57K
- Michael WongBel Air$31K
- Anna IrwinBethesda$30K
- Dontese NicholsonBaltimore$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.